NVision Imaging Technologies is pioneering advancements in quantum physics to facilitate the routine, cost-effective utilization of Magnetic Resonance Imaging (MRI) for evaluating early patient responses to cancer treatments at the metabolic level. By employing hyperpolarization, NVision enhances MRIs to efficiently measure natural metabolites, providing unprecedented cellular insights critical for assessing tumorous activity. Their technology, Polaris, is compact and straightforward, enabling metabolic MRI to be accessible in clinical and preclinical settings without significant infrastructure changes. This breakthrough allows for rapid, accurate differentiation between resistant and sensitive tumors soon after treatment begins, with potential applications extending beyond oncology into cardiology, hepatology, nephrology, neurology, and rheumatology. NVision is supported by deep-tech investors and collaborates with leading medical and research institutions across the US and EU.
MRI • NMR • Quantum Optics
October 19
Manage research partnerships for a biotech startup developing MRI technology.